To assess physician beliefs on the relative benefits of pens vs. vials, prescribing drivers, and characteristics of patients newly initiated on basal insulin analog via pens vs. vials among elderly type 2 diabetes patients. METHODS: An online survey of 352 U.S. primary care physicians was used to collect retrospective patient chart data on 500 elderly type 2 diabetes patients who initiated on basal insulin analog in 2009. For each physician, patient chart selection was randomized among eligible patients. Data on physician characteristics, physicians' opinion on the impact of different routes of administration (ROA), main drivers for selecting a particular ROA for each patient, and patient characteristics were collected. RESULTS: The majority of physician respondents were part of a group practice (77.8%) and treated a mean of 235.5 (SDϭ185.0) type 2 patients Ն 65 years old in 2009. Patient characteristics were similar in terms of age and diabetes duration. However, significantly more Caucasians (p ϭ 0.011) and patients covered by Medicare only (pϭ0.015) were initiated on pens, whereas significantly more women (pϭ0.003), Black/African Americans (pϭ0.011), and dual eligible patients (Medicare ϩ Medicaid; pϭ0.008) were initiated on vials. Patients initiated on vials had higher median baseline HbA1c values (8.7 vs. 8.4, pϽ0.001).Survey findings suggested that physicians prescribed vials primarily due to patients' economic constraints (62.9% of vial users vs. only 2.4% for pen users), although a majority of physicians considered pens better than vials (89.2% in terms of adherence, 65.1% in terms of HbA1c control, and 55.4% in terms of resource utilization). CONCLUSIONS: Results from this retrospective chart extraction survey suggest that patient characteristics differed between patients initiated on pens vs. vials, and that despite insulin pens being perceived as having better outcomes by physicians, economic considerations play a dominant role in the choice of insulin vials. 
PDB69 DIFFUSION OF NEW TECHNOLOGIES POST REIMBURSEMENT -MONITORING THE USE OF LIRAGLUTIDE IN PRIMARY CARE
St. James 's Hospital, Dublin, Ireland, Ireland OBJECTIVES: Liraglutide, a GLP-1 receptor agonist used to treat Type 2 diabetes patients, is reimbursed in Ireland since November 2009. Budget impact analysis at this time assumed use of the 1.2mg dose in 95% of patients. A 1.8mg maintenance dose is also available. The aim of this study was to examine utilisation of liraglutide in the post reimbursement 'real world' setting. METHODS: Data were analysed using a national prescription claims database from November 2009 to December 2011. Numbers of patients receiving prescriptions for liraglutide and exenatide were calculated per month and the average number of pens dispensed per prescription and duration of use was analysed for liraglutide. Drugs were classified and identified according to the WHO ATC classification system. Analysis was performed in SAS (v9.1). RESULTS: The number of prescriptions for liraglutide increased from 0.3 to 0.9/1000 GMS population over the study period. The number of exenatide prescriptions decreased from 0.3 to 0.15/1000 GMS population. Fifty percent of patients dispensed liraglutide in 2010 and 2011 received 1.8mg per prescription. The average duration of use of liraglutide ranged from Յ 3 months (41% of patients), Յ 6 months (26% of patients), Յ 9 months (18% of patients) and Յ 12 months (15% of patients). There was no correlation between the average duration of use and number of pens dispensed per prescription (Pearson correlation coefficient ϭ -0.05). CONCLUSIONS: Results from the study indicate that the higher daily dose (1.8mg) of liraglutide is used in 'real world' setting compared to pre-reimbursement assumptions. There are opportunity costs and clinical outcome implications arising from using the higher dose of liraglutide, given that there is no robust evidence of additional benefits on glycaemic control from the higher dose. This analysis highlights the role that monitoring can play in informing pharmacoeconomic evaluations and guideline recommendations post reimbursement. 
PDB70 CHARACTERISTICS OF LONG-ACTING SOMATOSTATIN (SSA) USE IN ACROMEGALY IN THE NETHERLANDS

OBJECTIVES:
To compare the potential cost of long-acting treatment with lanreotide vs octreotide for acromegaly using patient treatment characteristics from the PHARMO Record Linkage System (RLS) in the Netherlands. METHODS: A cost minimization model was used to compare the lifetime costs of the SSAs. Data for patients receiving outpatient dispensing of long-acting SSA (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) were selected from the PHARMO RLS. Acromegalic patients were identified by hospital discharge diagnoses and were stratified by first SSA dispensed during the study period. Dosing and injection intervals were assessed during stable treatment periods (i.e., the period of SSA dispensings with constant dosage and little variation in injection intervals). RESULTS: Sixty-two octreotide LAR users and 16 lanreotide Autogel users were identified. Stable treatment was observed in 46/62 (74%) octreotide users and 12/16 (75%) lanreotide users. The median (IQR) duration of the first stable phase was 3 (2-9) months for octreotide and 2 (1-3) months for lanreotide. During treatment stability, mean (ϮSD) injection intervals were 28 (Ϯ10) for octreotide and 30 (Ϯ6) for lanreotide; however, when patients were categorized into weekly intervals, there were more users on shorter intervals with octreotide than lanreotide (15/46 [33%] vs 2/12 [17%] injected every 3 weeks or more frequently and 9/46 [19%] vs 3/12 [25%] injected every 5 weeks or less frequently respectively). Based on similar dosing but longer injection intervals for lanreotide users, there appeared to be a 5% lower average cost per acromegalic patient treated with lanreotide over octreotide. CONCLUSIONS: The longer injection interval observed with the high dose lanreotide under stable long-acting SSA treatment resulted in reduced costs compared to octreotide. However, the patient numbers of this rare disease and the limited period of treatment stability limit the power to detect differences between preparations. OBJECTIVES: Although the primary goal among patients with type 2 diabetes (T2D) is gylcemic control, lack of patient education and health care access may represent a major obstacle to proper disease management, particularly in emerging markets such as Brazil. The aim of the current study was to document the level of patient knowledge of HbA1c levels and its effect on health outcomes. METHODS: Data were analyzed from the Brazil 2011 National Health and Wellness Survey, a crosssectional health survey of adults in Brazil (Nϭ12,000). Demographics (age, gender, education, socioeconomic status, insurance type), health history (HbA1c level, FPG level, frequency of testing), and health outcomes (health status using the SF-12v2, work productivity loss using the WPAI, and health care resource use) were assessed for all respondents. RESULTS: A total of 480 respondents (4.0%) reported a diagnosis of T2D of whom 85.38% did not know their level of HbA1c. Among those who were aware of their HbA1c level, 60.34% reported being uncontrolled (i.e., a level greater than 7%). Patients who were uncontrolled reported significantly worse physical health status (39.43 vs. 46.68) and a significantly greater percentage work overall impairment (42.93% vs. 25.58%) compared with those who were controlled (all pϽ.05). Access to care also was associated with better outcomes as those with private insurance were significantly more likely to have an HbA1c test in the past 3 months (15.57% vs. 6.57%) and significantly less likely to have never been tested (38.32% vs. 43.01%) than those with just public insurance (all pϽ.05).
PDB71 PATIENT ACCESS, HBA1C KNOWLEDGE, AND HEALTH OUTCOMES AMONG TYPE 2 DIABETES PATIENTS IN BRAZIL
CONCLUSIONS:
The lack of awareness of HbA1c levels suggests a significant gap in patient education. Given the high probability of being uncontrolled, this lack of patient education may have significant humanistic and economic consequences for Brazil from a societal perspective. Improvement in access and education may help improve overall T2D management. A search of electronic databases [international and national] and hand search of reference lists of key publications was performed. A methodological quality assessment of reviewed publications applying the Center for Evidence Based Medicine (CEBM, 2012) tool was performed. All costs updated to €, 2011. RESULTS: A total of 1505 articles were identified, 639 were excluded and 28 were retrieved. Total national health care expenditure intended for DM2 care in Spain was about €2,800 million per year. Direct costs varied between €851.23 and €4,882.80 per patient/year. Main cost drivers were: other pharmacological treatments different from antidiabetics (37.83%), hospital admissions (31.93%), medical visits (25.57%), and oral antidiabetics (4.67%). Severe and moderate hypoglycemias increased costs 174 and 8 times, respectively, compared to those episodes with no need of medical care. DM2 costs increased by 59.5% if the goal of HbA1cϽ7% was not reached; by 30% with obesity, and by 64.5% if disease related complications appeared. Each 10% raise in adherence to oral antidiabetic treatment represented a 2% to 4% reduction in DM2 costs. Levels of CEBM recommendation were 2c (16 studies), 3b (8 studies) and 4 (4 studies). CONCLUSIONS: Main factors directly associated to costs of DM2 care in Spain were hypoglycemia, DM2 related complications, HbA1c control, obesity and treatment adherence. Strategies aimed to improve these factors would have a major impact on costs reduction. 
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